MAPT and Alzheimer disease: As studies show that tau pathology can be reduced by Aβ clearance in transgenic AD mice and AD patients [19], we tested whether chemical-driven Aβ disaggregation by YIAD compounds affected tauopathy in 5XFAD mice.